Fortress Biotech, Inc. (FBIO)

NCM – Цена в реальном времени. Валюта: USD

2.26

+0.02 (0.89%)

При закрытии: May 12, 2026, 4:00 PM EDT

2.25

-0.01 (-0.36%)

До открытия: May 13, 2026, 5:46 AM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Fortress Biotech, Inc. (FBIO)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Fortress Biotech, Inc. (FBIO)

Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026

Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™

Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights

Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million

Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026

Видео

No Data

Пресс-релизы

Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™

Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights

Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million

Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

Search stocks

Fortress Biotech, Inc. (FBIO)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Fortress Biotech, Inc. (FBIO)

Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026

Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™

Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights

Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million

Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026

Видео

No Data

Пресс-релизы

Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™

Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights

Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million

Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights